Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05239546 · ClinicalTrials.gov registry record · Phase 2
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
A Phase 2 study of Colon Cancer and DMMR Colorectal Cancer, sponsored by University of Iowa.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05239546 is a Phase 2 study of Colon Cancer and DMMR Colorectal Cancer that is actively recruiting participants, run by University of Iowa. The registered enrollment target is 25 participants, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05239546, a Phase 2 study of Colon Cancer and DMMR Colorectal Cancer, is actively recruiting participants, sponsored by University of Iowa.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase II, single arm study looking at the rate of major clinical response and non-operative management in Stage II and III colon cancer after 18 weeks (up to 6 cycles) of neoadjuvant dostarlimab.
Conditions Studied
Interventions
- DRUG Dostarlimab
Study Locations (1)
Iowa
- University of Iowa Hospitals & Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-03-24 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05239546
The ClinicalTrials.gov registry entry for NCT05239546 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colon Cancer appearing as the primary indexed condition, and to 1 intervention - of which Dostarlimab is the first listed.
NCT05239546 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT05239546 about?
NCT05239546 is a clinical study titled "Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers". This is a Phase II, single arm study looking at the rate of major clinical response and non-operative management in Stage II and III colon cancer after 18 weeks (up to 6 cycles) of neoadjuvant dostarlimab.
What is the current status of trial NCT05239546?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2023-03-24. Estimated completion is 2029-06-30.
What conditions does trial NCT05239546 study?
This clinical trial studies the following conditions: Colon Cancer, DMMR Colorectal Cancer.
What interventions are being tested in trial NCT05239546?
The interventions under investigation include: Dostarlimab (DRUG).
Who is sponsoring clinical trial NCT05239546?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05239546 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 2
-
Phase II Trial of Lung Chemoemobolization
RECRUITING · Phase 2
-
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
RECRUITING · Phase 2
-
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Clinical Trial in Patients With Metastatic Colorectal Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.